Research Note: Validation of a new differentiation approach using the commercial ASAPTM media to detect the Salmonella 441/014 vaccine strain.

Vaccination is one of the most important control tools to reduce Salmonella in poultry production. In order for a live vaccine to be licensed for field use it should be provided with the detection methods to differentiate it from field strains. This paper aims to describe the validation of an alternative method for the differentiation of the Salmonella 441/014 vaccine strain from field strains, using a chromogenic Media, ASAP from bioMérieux. The ASAP-based differentiation method was compared with already authorized methods, namely the Anicon SE Kylt PCR DIVA 1 assay and Ceva S-Check Salmonella differentiation kit, following the ISO 16140-6:2019 validation method guidelines. A Generalised Linear Model was fitted to the data to determine the inclusivity and exclusivity of differentiation methods (PCR Kylt vs. S-Check vs. ASAPTM). Statistical differences were based on a P-value level of < 0.05 (SPSS Inc., Chicago, IL). In this study, we show that the ASAP media was able to differentiate Salmonella Enteritidis vaccine strains from field strains, obtaining 100% agreement between the three differentiation assays. This differentiation approach is quicker, easier to deploy and cheaper as compared to alternative methods.

Fibroblast growth factor 21 and fructose dynamics in humans.

Objective: Fructose consumption is a risk factor for metabolic disease. We recently demonstrated that fibroblast growth factor 21 (FGF21), a metabolic hormone involved in lipid and glucose metabolism, is acutely stimulated in humans by 75 g oral fructose, with peak levels occurring 2 h after consumption. This study reports on the dose dependency and reproducibility of the FGF21 response to fructose. Methods: Lean, healthy adults drank either five different doses of fructose dissolved in water, each separated by 2 weeks, or the same dose on three occasions, each separated by 1 week. Results: Fibroblast growth factor 21 levels peaked at 2 h in a dose-dependent manner. No significant increase in FGF21 was seen after consumption of 10 g fructose, while robust increases were seen after drinking solutions containing 30, 50 and 75 g. At 2 h, the minimal fold change of FGF21 was highest following a 75 g fructose drink, and all subjects demonstrated at least a doubling of FGF21 levels following consumption of this dose. Conclusions: The increase in FGF21 following an oral fructose challenge is dose dependent, with levels peaking at 2 h independent of dose. The FGF21 response to 75 g fructose is also highly reproducible within individuals. Clinical Implications: By demonstrating that the FGF21 response to fructose is dose dependent and reproducible, this study deepens current understanding of FGF21 fructose dynamics and physiology in humans. This is an important area of clinical interest given associations between fructose intake and a wide variety of metabolic derangements.

Recovery of molybdenum, nickel and cobalt by precipitation from the acidic leachate of a mineral sludge.

The objective of this study was to investigate the recovery potential of molybdenum (Mo), nickel (Ni) and cobalt (Co) from synthetic and real acidic leachate of a mineral sludge from a metal recycling plant by sulfide precipitation. The operational parameters (metal sulfide (M/S) ratio 0.1-1, agitation speed 0-100 rpm, contact time 15-120 min and pH 1-5) were optimized in batch conditions on synthetic metal leachate (0.5 M HNO3, Mo = 101.6 mg L(-1), Ni = 70.8 mg L(-1), Co = 27.1 mg L(-1)) with a 0.1 M Na2S solution. Additionally, recovery of the target metals was theoretically simulated with a chemical equilibrium model (Visual MINTEQ 3.0). The optimized Na2S precipitation of metals from the synthetic leachate resulted in the potential selective recovery of Mo at pH 1 (98% by modeling, 95% experimental), after simultaneous precipitation of Ni and Co as sulfide at pH 4 (100% by modeling, 98% experimental). Metal precipitation from the real leachate (18 M H2SO4, Mo = 10,160 mg L(-1), Ni = 7,080 mg L(-1), Co = 2,710 mg L(-1)) was performed with 1 M Na2S, and resulted in a maximal Mo recovery at pH 2 (50%), while maximal recoveries of Ni and Co were observed at pH 4 (56% and 60%, respectively). Real leachate gave a lower metals recovery efficiency compared with synthetic leachate, which can be attributed to changes in the pH, nature of leachant, co-precipitation of Zn and competition for S(2-) ions.

Acid extraction of molybdenum, nickel and cobalt from mineral sludge generated by rainfall water at a metal recycling plant.

This study investigated the leaching yields of Mo, Ni and Co from a mineral sludge of a metal recycling plant generated by rainfalls. The investigated mineral sludge had a complex heterogeneous composition, consisting of particles of settled soil combined with metal-bearing particles (produced by catalysts, metallic oxides and battery recycling). The leaching potential of different leaching reagents (stand-alone strong acids (HNO3 (68%), H2SO4 (98%) and HCl (36%)) and acid mixtures (aqua regia (nitric + hydrochloric (1:3)), nitric + sulphuric (1:1) and nitric + sulphuric + hydrochloric (2:1:1)) was investigated at changing operational parameters (solid-liquid (S/L) ratio, leaching time and temperature), in order to select the leaching reagent which achieves the highest metal leaching yields. Sulphuric acid (98% H2SO4) was found to be the leachant with the highest metal leaching potential. The optimal leaching conditions were a three-stage successive leaching at 80 °C with a leaching time of 2 h and S/L ratio of 0.25 g L(-1). Under these conditions, the achieved mineral sludge sample leaching yields were 85.5%, 40.5% and 93.8% for Mo, Ni and Co, respectively. The higher metal leaching potential of H2SO4 in comparison with the other strong acids/acid mixtures is attributed to the fact that H2SO4 is a diacidic compound, thus it has more H(+) ions, resulting in its stronger oxidizing power and corrosiveness.

Fox baiting against Echinococcus multilocularis: contrasted achievements among two medium size cities.

In Europe, most cities are currently colonized by red foxes (Vulpes vulpes), which are considered to be the main definitive host of the zoonotic cestode Echinococcus multilocularis. The risk of transmission to humans is of particular concern where high fox populations overlap with high human populations. The distribution of baits containing praziquantel has successfully reduced the infection pressure in rural areas and in small plots within large cities. The purpose of this study was to assess its efficiency in two medium size cities (less than 100,000 inhabitants) in areas of high human alveolar echinococcosis incidence. From August 2006 to March 2009, 14 baiting campaigns of praziquantel treatment were run in Annemasse and Pontarlier (Eastern France), each of which encompassed 33 km(2), with a density of 40 baits/km(2). The bait consumption appeared to be lower in strictly urban context compared to suburban areas (78.9% vs. 93.4%) and lower in Annemasse than in Pontarlier (82.2% vs. 89.5%). During our study, the prevalence of E. multilocularis, as assessed by EM-ELISA on fox faeces collected in the field in Annemasse, was lower within the treated area than in the rural control area. A "before/during" treatment comparison revealed a significant decrease of spring prevalence from 13.3% to 2.2%. No significant change in prevalence was detected in Pontarlier (stable prevalence: 9.1%) where the contamination of the treated area followed the temporal trend observed in the control area. There, a greater resilience of the parasite's life cycle, probably due to a strong pressure of recontamination from outside the treated area, may have counteracted the prophylaxis treatment. These contrasted outcomes suggest that the frequency of fox anthelmintic treatment should be adapted to the local situation.

Biosorption properties of extracellular polymeric substances (EPS) towards Cd, Cu and Pb for different pH values.

The aim of this study was to assess the influence of pH on the metal biosorption of extracellular polymeric substances (EPS) extracted from two different activated sludges called A and B. The composition and physico-chemical characteristics of EPS were determined. The biosorption capacities of the EPS were examined at pH 4, 6, 7 and 8 successively with three metals Cu, Pb and Cd using differential pulse polarography (DPP) as an investigation tool and Ruzic's model was used to produce polarographic titration curves. Two apparent pKa were obtained, the first were 6.6 (EPS A) and 5.7 (EPS B), attributed to carboxylic and phosphoric groups whereas the second was 8.7 for EPS A and 9.4 for B and these were attributed to phenolic and amino functional groups. Whatever the EPS and the metal considered, the conditional binding constant did not show significant differences in the strength of complex formed between the EPS and metals. But for all metals, the number of EPS binding sites was significantly lowered by a decrease in the pH of the medium. At pH 4, the metal biosorption capacity of EPS is very low. At pH 6, the number of EPS binding sites increased in the following order: Pb>Cu>Cd whereas at pH 7 and 8, this order changed and was: Cu>Pb>>Cd. Simulations of the speciation states of Cu, Pb and Cd at the different pH values in ultra-pure water (25 degrees C, ionic strength 0.045 M) were performed with MINEQL 4.5 software and indicated the presence of hydroxylated forms and sometimes solid forms for Pb and Cu. But the polarographic titration curves revealed precipitation of Cu only at the end of the experiments at pH 8.

[Epidemiology and costs of lung cancer in France]. / Epidémiologie et coûts du cancer du poumon en France.

There were 21,850 cases of newly diagnosed lung cancers in France in 1995. This figure corresponds to an incidence rate (standardized to the population of Europe) of 66.5 per 100,000 men and 8.9 per 100,000 women. The incidence is age-related and reaches a peak between 70 and 74 years of age for men and between 75 and 79 years of age for women. The incidence also varies by region and the highest rates were observed in east of France. Non-small-cell lung cancers represent 80% of all lung cancers. Between 1985 and 1995, as a result of changes in tobacco consumption, the incidence rates increased by 56% in women and by 5% in men under the age of 65. The incidence rates in France are close to the average rates observed in Europe. In 1995, lung cancers led to 23,900 deaths in France (mortality rate standardized to Europe: 36.6 per 100,000). 85% of deaths due to lung cancer occurred among men. Prognosis of lung cancer remains poor and has not improved appreciably over the last two decades. 58% of all patients died during the first year and 82% during the three years following lung cancer diagnosis. Survival rates appear to be better for patients with non small cell lung cancer than for patients with small cell lung cancer. Few studies have addressed the economics of lung cancer in France. Cost-of-illness studies of lung cancer were published mainly in Canada, the Netherlands and Australia. These analyses have included descriptive works as well as economic models based on theoretical diagnostic and treatment algorithms.

International validation of the CLAU-S quality-of-life questionnaire for use in patients with intermittent claudication.

BACKGROUND: Intermittent claudication (IC) occurs in patients with peripheral occlusive arterial disease and results in leg pain after walking a certain distance - the claudication distance. Until recently, no specific questionnaire has been available to measure quality of life in patients with IC. OBJECTIVES: To validate the Claudication Scale (CLAU-S) questionnaire in patients in France, the UK, Germany and Belgium. METHODS: Patients completed the CLAU-S questionnaire and provided demographic and clinical data. Pooled data were examined for psychometric and structural validity and test-retest reliability. Structural equation modelling (SEM) was used to confirm that the questionnaire was measuring the causal relationships involved in IC in each of the language groups studied. RESULTS: Cross-sectional and factor analysis confirmed the validity of the questionnaire in the pooled patient population. Item convergent and discriminant coefficients and internal consistency reliability coefficients met or exceeded standard criteria. Principal component analysis confirmed the factorial structure. The underlying causal relationships in IC were identified using SEM and were consistent in all language groups studied. CONCLUSIONS: The CLAU-S questionnaire has undergone validation in English, French, German and Flemish and has a very satisfactory validity in these languages.

The long-term cost-effectiveness of improving alcohol abstinence with adjuvant acamprosate.

A computer model was developed with decision analysis software to explore the long-term clinical and economic outcomes of alcohol abstinence maintenance with either standard counselling therapy or standard therapy plus 48 weeks of adjuvant acamprosate in detoxified alcoholic patients. Important complications of alcoholism were modelled using Markov processes, and included relapse (return to drinking), alcohol-related hepatic disease, acute and chronic pancreatitis, acute and chronic gastritis, oropharyngeal carcinoma, oesophageal carcinoma, alcoholic cardiomyopathy, alcohol-related peripheral neuropathy, alcoholic psychosis, accidental death, and suicide. Probabilities of developing complications were dependent on whether the patients within the cohort remained abstinent or had relapsed. Relapse rates, probabilities, and costs for acamprosate therapy and treatment of complications were taken from published literature. The analysis was performed from the German health insurance perspective. Life expectancy and total lifetime costs (costs of initial abstinence maintenance therapy plus costs of complications) were calculated for a typical male cohort with average age of 41 years, 80% with fatty liver, 15% with cirrhosis, 22% with chronic pancreatitis, and 1% with alcoholic cardiomyopathy at baseline. Life expectancy with and without acamprosate therapy was 15.90 and 14.70 years respectively, and discounted (5% per annum) average total lifetime costs per patient were DEM 46 448 and DEM 49 549 respectively. We conclude that, despite the acquisition costs of DEM 2177, adjuvant acamprosate therapy was both clinically and economically attractive under conservative assumptions.

[Intermittent claudication and quality of life. Psychometric validation of the French version of the CLAU-S questionnaire]. / Intermittent claudication and quality of life. Psychometric validation of the French version of the CLAU-S questionnaire.

CLAU-S is a disease-specific quality of life (QoL) scale for patients with intermittent claudication due to peripheral arterial disease of the lower limbs. Initially developed in Germany, the scale has been translated into French according to classical forward/backward methodology. The objective of this study was to test the validity of the French version of CLAU-S. In its current format, the CLAU-S scale evaluates 5 dimensions: "Daily Living"; "Pain"; "Social Life"; "Disease-specific anxiety"; and "Mood", for a total of 47 items. The QoL scores and clinical findings in 157 patients with intermittent claudication were analysed. Validation of the convergence and discriminatory power of the scale were confirmed. Analysis of structural validity showed grouping of items in accordance with initial scale construction and a clear separation between the different dimensions. Analysis of the internal reliability of the questionnaire confirmed the good internal coherence of these dimensions. Reproducibility of the scores over time was confirmed by test-retest analysis. In addition to the actual validation of CLAU-S, a new, innovative mathematical technique called Structural Modelling Equations was used on this QoL instrument. It related the causal structure of the QoL components in peripheral arterial disease of the lower limbs (stage 2). An indisputable causal relationship was demonstrated between clinical parameters, particularly walking distance, and the QoL components. The classical symptom-deficit-disability causal structure of disease- specific QoL questionnaires was also studied. In particular, we found an essential relationship between the Daily Living dimension and, to a lesser extent, the Social Life activities and Disease- specific anxiety dimension, and QoL. The Pain dimension proved to be an explanatory variable of the other QoL components without being directly related to QoL. Finally, the Mood dimension was a resultant variable of QoL and not an explanatory variable of QoL. This study therefore enabled validation of the psychometric properties of the French version of CLAU-S and also demonstrated the complementary roles of walking distance and QoL in the management of patients with intermittent claudication.

[Consequences of obliterating arteriopathy of the legs on the professional activity of patients and external assistance]. / Conséquences de l'artériopathie oblitérante des membres inférieurs (AOMI) sur l'activité professionnelle des patients et sur les aides extérieures.

Peripheral arterial occlusive disease of the lower limbs results in increased risks of cardiovascular and cerebrovascular morbidity and mortality. However, peripheral arterial disease also has an incapacitating effect upon patients' daily lives, and indeed can have considerable consequences upon their quality of life as well as upon their professional activities. The purpose of this study was to describe patients in terms of their professional activities, the consequences of the disease upon such activities, need for external assistance, and the effects of treatment over a six-month treatment follow-up period. This was a prospective, randomised, double-blind, multicentre study comparing naftidrofuryl (three 200-mg tablets per day) versus placebo in patients presenting with stage-II peripheral arterial disease. Four study visits were scheduled for each patient: an initial selection visit, followed by a 30-day placebo wash-out period, an inclusion visit (to allow verification of inclusion and non-inclusion criteria), and follow-up visits after 3 and 6 months of treatment. 234 patients were included in the study in intention to treat (117 patients in the naftidrofuryl group and 117 patients in the placebo group). These two groups were entirely comparable for all criteria (sociodemographic criteria, risk factors, cardiovascular history, duration of disease) except for obesity and dyslipidaemia, for which prevalence was higher in the naftidrofuryl group. 12.4% of the study population were professionally active at the time of the survey (mean age: 65.9 years). However, 42.3% of patients had in fact been active at the time when arterial disease became manifest. Of these patients, 45.4% (45 patients) stated that arterial disease had affected their professional activity: 28.9% (13 patients) reported a change in their activity, 26.7% (12 patients) reported partial suspension of their activity, and 44.4% (20 patients) stated that all professional activities had ceased. Changes in professional activity comprised invalidity (36.2%), prolonged sick leave (25.5%), premature retirement (14.9%), sick leave (17%), unemployment (6.4%), reduction in long-distance travel (4.3%), change of job (8.5%) or salary reduction (2.1%). During the 6-month follow-up period, only 4 patients were on sick leave (3 in the placebo group and 1 in the naftidrofuryl group). Furthermore, less than 10% of the study population required external assistance as a result of the disease. This analysis thus highlights the repercussions of this disease upon the patients' daily and professional activities.

Glycemic control and cardiovascular disease in type 2 diabetes: a review.

Cardiovascular disease is the major cause of morbidity and mortality in people with Type 2 diabetes, and risk of atherosclerotic disease is markedly increased in people with diabetes compared to people with normal glucose tolerance. The excess risk can not be completely explained by increased prevalence of other cardiovascular disease risk factors such as hypertension and hyperlipidaemia in people with diabetes. This review examines the role of hyperglycemia and glycemic control in cardiovascular disease in people with Type 2 diabetes. The results of prospective observational studies and randomized controlled trials are summarized. We conclude that control of hypertension and hyperlipidemia are important to reduce risk of cardiovascular disease in people with diabetes and may be more easily achieved than tight glycemic control.

[Changes in prescription patterns for peripheral and cerebral vasoactive drugs before and after establishing prescription standards in France]. / Evolution de la prescription des vaso-actifs périphériques et cérébraux avant et après les références médicales opposables.

OBJECTIVES: Assess changes in the number of prescriptions for peripheral and cerebral vasoactive drugs for the treatment of lower limb arteritis and cerebrovascular disease since the promulgation in 1995 of prescription standards for the treatment of lower limb arteritis. Assess compliance to prescription standards with a detailed analysis of patient features, prescriptions written for lower limb arteritis, cerebrovascular disease and concomitant diseases and evaluate changes in treatment costs for lower limb arteritis and cerebrovascular disease as well as cost of the full prescription, including treatments for associated diseases. METHODS: This study was based on data recorded during the Permanent Study of Medical Prescriptions conducted from March 1994 to February 1995 and from March 1995 to February 1996 by the IMS. Prescription costs were established from the National Description Files of the IMS. Treatment costs were expressed as public price (FF) tax included. Prescriptions meeting the following criteria were selected for each period: prescriptions written by general practitioners for drugs with peripheral and cerebral vasoactivity (excepting calcium antagonists with a cerebral target) belonging to the Anatomic Therapeutic Classes C4A1 of the European Pharmaceutical Marketing Research Association, Bromly 1996; prescriptions for diagnoses 447.6 (arteritis) and 437.9 (cerebrovascular disease) according to the 9th WHO classification. A random sample of 500 prescriptions was selected to calculate costs. RESULTS: Since the advent of the prescription standards in 1995, prescriptions have dropped off by 6.3% for lower limb arteritis and by 14.8% for cerebrovascular disease. There was a 3.7 point decline in the percentage of multiple prescriptions of vasoactive drugs for lower limb arteritis (21.7% prior to March 1995 versus 18% after promulgation of the prescription standards, p > 0.1) and a 1.8 increase in the percentage of multiple prescriptions for cerebrovascular disease (14% prior to March 1995 and 15.8% after promulgation of the prescription standards, p > 0.1). For the treatment of lower limb arteritis, prescription costs fell by a mean 9% per prescription and for the treatment of cerebrovascular disease they rose by a mean 7% per prescription. The price rise, due to multiple prescriptions of vasoactive drugs was 190 FF per prescription for lower limb arteritis and 104 FF per prescription for cerebrovascular disease. CONCLUSION: Despite the retrospective nature of this study where confounding factors could not be controlled, our findings are in agreement with those reported earlier suggesting that cost containment policy implemented by the prescription standards has had little efficacy. In patients with arterial disease of the lower limbs, the percentage of prescriptions not complying with the recommended standards decreased by one-third to one-half over a 2-year period since the prescription standards were first announced in 1994.

Peripheral arterial obliterative disease. Cost of illness in France.

The main purpose of this study, carried out in 1995, was to determine, using available sources, the cost of peripheral arterial obliterative disease (PAOD) in France over a 1-year period. This cost-of-illness study was based on a retrospective analysis of the available literature and databases. It involved a description of epidemiological data and a cost estimate of the different medical resources consumed over 1 year. For this latter purpose, a payer perspective was chosen. Data were extracted from national representative surveys and databases with respect to morbidity and mortality [from the National Institute of Health and Medical Research (Institut National de la Santé et de la Recherche Médicale; INSERM) and the National Sickness Insurance Fund for Salaried People (Caisse Nationale d'Assurance Maladie des Travailleurs Salariés; CNAMTS)], consultations, examination tests and drug prescriptions [from the French Medical Audit conducted by Intercontinental Medical Statistics (IMS)], hospitalisations [from the Statistical Unit of the Department of Health-Service des Statistiques, des Etudes et des Systemes d'Information (SESI) and the National Public Research Centre in Health Economics (Centre de Recherche d'Etude et de Documentation en Economie de la Santé; CREDES)] and related health expenditure from CNAMTS. In France, the prevalence of stage II PAOD (Leriche and Fontaine classification) in 1992 was estimated to be 675,000; 53% of these patients had undergone vascular or bypass surgery. The total annual cost of healthcare (including consultations, drugs, laboratory tests, hospitalisation and hydrotherapy) for the management of patients with PAOD ranged from 3.9 billion French francs (F) to F4.6 billion (1995 values), depending on the type of hospital considered. 50% of this cost was related to hospitalisations and 75% was covered by the CNAMTS. Although this study was only a partial evaluation and did not take into account indirect costs or nonmedical direct costs, such as transport and care by healthcare assistants and paramedics, these results may help to establish public health priorities and modify clinical practice to favour an earlier diagnosis of PAOD.

Naftidrofuryl in intermittent claudication: a retrospective analysis.

A retrospective analysis was performed on all five published clinical trials in which naftidrofuryl was given at a dosage of 600 mg daily. Two studies were undertaken in France, two in Germany, and one in Great Britain. Data for the analysis, which included the presence of risk factors, treadmill walking distances, and cardiovascular critical events that occurred during the course of the study, were generated from the patients' original study file. Included in the analysis were 888 patients, 447 receiving naftidrofuryl and 441 receiving placebo. Although there were significant differences between the studies with regard to certain variables, distribution was comparable between the treatment groups justifying an analysis on the pooled sample. An intention-to-treat analysis based on a success/failure outcome was in favor of active treatment (p = 0.003) as was an analysis of change in pain-free walking distance (PFWD) (p < 0.002). None of the risk factors had any significant influence on change in PFWD. A further analysis indicated that there were significantly fewer cardiovascular critical events in the naftidrofuryl group than in the placebo group (p = 0.029). Because the incidence of cardiovascular critical events was lower in those patients who showed the greatest improvement in PFWD, and as surgical intervention was the most frequently encountered critical event, it is possible that treatment with naftidrofuryl may lead to a reduction or postponement of surgery. Such a finding would have implications for health-care resources.

[Prediction and prognosis of diabetes incidence in treated hypertensive patients]. / Prédiction et pronostic du diabète incident chez l'hypertendu traité.

The study is based on a clinical population of 1962 hypertensive men and women consecutively examined as in- or out-patients in our clinic from Jan. 1967 to Dec. 1976. Those having a diabetes (treated for diabetes, or fasting glycemia greater than or equal to 7.75 USI) at initial exam were excluded. In february 1977, all were contacted by mail. 89 p. 100 of the subjects still living at the same address answered. 74 "cases" had developed a diabetes (clinical diagnosis, or fasting glycemia greater than or equal to 9.5 USI); they were matched with "controls" according to sex, age (+/- 2), and date of entry (+/- 4 months); all the controls had answered that they were not diabetic in Feb. 1977. At initial exam, the following abnormalities were significantly more pronounced in cases than in controls (by decreasing level of significance): glycemia 1 h. after glucose load, weight index (W/H2), fasting glycemia (p less than 0.001); ECG abnormalities of T (Minnesota code 5.1-3), and J-ST (4.1-3) (p less than 0.01); angina (p less than 0.05). Incidence of diabetes was studied in the basal population, by life table method, according to two abnormalities: relative weight greater than or equal to 115 p. 100, glycemia after load greater than or equal to 8.33. At five years, the estimations were: 0 p. 100 in both sexes, when both abnormalities were absent; 20 p. 100 in men and 31 p. 100 in women when both abnormalities were simultaneously present; 4 p. 100 in men and 2 p. 100 in women in other cases.(ABSTRACT TRUNCATED AT 250 WORDS)